Cure closes $20M CBD acquisition
Cure Pharmaceutical, an Oxnard cannabis products manufacturer, has completed its $20 million cash-and-stock buyout of the CBD company Sera Labs, a deal Cure says will help it reach positive cash flow in around 18 months. Cure’s stock, which is traded on the over-the-counter markets, fell 3 percent following the announcement, closing at $1.29 per share Read More →
Oxnard’s Cure makes $20M buy of CBD firm
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Oxnard company Cure Pharmaceutical gets DEA license for cannabis products
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Putting cures on a strip: Startup makes medicines for the third world
An Oxnard-based startup puts medicines and nutritional supplements on easy-to-use, Listerine-like strips that dissolve in the mouth.
